HVTN 142
STUDY BASICS
Are you 18 to 55 years old and in good health? You may be eligible to participate in a research study to test an experimental vaccine against HIV. This study wants to see if the study vaccine is safe and how a person’s immune system responds to it. Compensation is provided.
STUDY PURPOSE
The purpose of this study is to see if the study vaccine is safe and how a person’s immune system responds to it.
This study hopes to answer several main questions:
- Is the study vaccine safe to give to people?
- Are people able to take the study vaccine without becoming too uncomfortable?
- How do people’s immune systems respond to the study vaccine? (Your immune system protects you from infections and diseases.)
- Does the virus used to make the study vaccine show up in people’s body fluids?
This study is testing an experimental HIV vaccine. The study vaccine is called VIR-1388.
COULD THIS STUDY BE RIGHT FOR YOU?
- Age 18-55
- In overall good health
WHAT PARTICIPANTS CAN EXPECT
- 16-20 scheduled visits over approximately 12 months.
- Participants may be asked to come back for clinic visits for long term follow-up at 2 years and 3 years after their injection. Long term follow-up is optional.
IRB: SSU00213622B
- Vir Biotechnology, Inc. - HVTN 142, A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV (Pro00070151)MEET THE RESEARCHER

Madhu Choudhary
Madhu Choudhary is an Associate Professor in the Division of Infectious Diseases in the Department of Medicine at the University of Pittsburgh. A graduate of Maulana Azad Medical College, Dr. Choudhary’s research interests include HIV and viral hepatitis therapeutic clinical trials.